The relation between plasma miR-126 levels and cerebral collateral circulation in patients with intracranial arterial stenosis

Xiwa Hao1,2,3,*, Shuwan Wang1,3,*, Changchun Jiang1,2,3, Jingfen Zhang1,2,3, Yu Fan1,2,3, Jiangxia Pang1,2, Tianyou Zhang1,3, Fei Hao1, Junfeng Yang1,2, Xia Li1,2, Jiahui Liu1,2, Baojun Wang1,2,3, Yuechun Li1,2,3

1Department of Neurology, Baotou Central Hospital, Inner Mongolia, China
2Institute of Cerebrovascular Disease in Inner Mongolia, Inner Mongolia, China
3Clinical Research Centre for Neurological Diseases in Inner Mongolia Autonomous Region, Inner Mongolia, China

Abstract

Objective. This study aimed to investigate the correlation between the circulating miR-126 regulation pathway and the cerebral collateral circulation (CCC), and to test whether miR-126 could serve as a potential biomarker for CCC formation in patients with intracranial arterial stenosis or occlusion.

Material and methods. This single-centre cross-sectional study enrolled patients who underwent cerebral angiography with severe stenosis (≥70%) or occlusion in at least one major intracranial artery. Collateral degree was graded according to the ASITN/SIR classification. The patients were divided into a good CCC group (grade 3–4) or a poor CCC group (grade 0–2). We investigated the plasma levels of miR-126, VEGF, Spred-1 and PIK3R2 by using qRT-PCR, ELISA and Western blot methods, respectively. In addition, we assessed the correlations of plasma miR-126 with VEGF, Spred-1, PIK3R2 and ASITN/SIR grade using the Spearman correlation test and investigated its predictive power for CCC status by using the receiver operating characteristic curve.

Results. A total of 68 patients were enrolled (44 with good CCC and 24 with poor CCC). Data showed that plasma miR-126 and VEGF were significantly higher in the good CCC group than in the poor CCC group. Plasma Spred-1 and PIK3R2 level were lower in the good CCC group than in the poor CCC group. In addition, miR-126 and VEGF were positively correlated with ASITN/SIR (miR-126: R = 0.595, P < 0.01; VEGF: R = 0.595, P < 0.01), whereas Spred-1 and PIK3R2 were negatively correlated with ASITN/SIR (Spred-1: R = -0.817, P < 0.01; PIK3R2: R = -0.513, P=0.01). However, the area under the curve of miR-126 level for CCC status was only 0.328 (95% CI: 0.158–0.498; p = 0.067).

Conclusions. Plasma miR-126 level may be related to better CCC formation, one of the mechanisms that may be explained by upregulation of VEGF and reduction of Spred-1 and PIK3R2 protein expression. However, miR-126 might not be an independent predictor for CCC, given its low predictive value.

Key words: miR-126, VEGF, cerebral collateral circulation, ASITN/SIR, biomarker

Introduction

Acute ischaemic stroke can result in severe neurological disability and/or death [1]. The cerebral collateral circulation (CCC) is a network of blood vessels designed to preserve cerebral blood flow when primary routes fail [2]. Several recent studies have provided information about the role of collaterals in stroke pathophysiology, and it has been recognised that collateral circulation influences arterial recanalisation, reperfusion, haemorrhagic transformation and neurological outcomes after stroke [3–7]. To date, the CCC has mainly been assessed by using expensive or invasive imaging techniques.
The strength of the CCC varies among patients and partly depends on genetic and modifiable risk factors. Therefore, the identification of a biomarker of CCC status would be of considerable clinical significance.

MiRNAs are small non-coding RNAs (~22 nucleotides) that suppress translation or induce degradation of downstream mRNA targets, thereby modulating gene expression at the post-transcriptional level [8]. Studies have shown that miRNAs play an important role in arteriogenesis and vascular remodeling [9, 10]. Among the several miRNAs, miR-126 has appeared to be enriched in tissues with a high vascular component and to be specific to the vascular system [11, 12]. miR-126, an endothelial cell-specific miRNA, modulates angiogenesis in vivo by enhancing the proangiogenic actions of VEGF, and repressing the expression of Spred-1 and PIK3R2 [13, 14]. It has been reported that there is a close relationship between miR-126 and coronary collateral vessel function, and these are considered as circulating biomarkers to identify insufficient or sufficient collateralisation in patients with chronic coronary occlusion [15, 16]. Although miR-126 plays an important role in collateral circulation formation of the coronary artery, the correlation between miR-126 and the CCC has not been investigated.

In this single-centre cross-sectional study, we enrolled patients who underwent cerebral angiography with severe stenosis (≥ 70%) or occlusion in at least one major intracranial artery. We aimed to investigate the correlation between the circulating miR-126 regulation pathway and the CCC, and to test whether miR-126 could serve as a potential biomarker for CCC formation.

Materials and methods

Study design and population

Inclusion criteria of this single-centre cross-sectional study were: (1) age 35–80 years; (2) hospitalised in the neurological department and having undergone cerebral angiography at Baotou Central Hospital; (3) having severe stenosis (≥ 70%) or occlusion in at least one major intracranial artery; (4) refusal to sign an informed consent form; (5) Western blot method for Spred-1 and PIK3R2

The whole blood total protein extraction kit (BB-3410, BestBio) was used to extract the total protein of the fasting blood sample. The bicinchoninic acid (BCA) quantitative kit was used to quantify the total protein. Protein concentrations were determined using a BCA protein assay kit (P0010, Thermo Fisher Scientific). The total protein concentration was determined by measuring the absorbance at 562 nm. The protein concentration was calculated using the BCA reagent and bovine serum albumin as the standard.


determination of plasma miR-126

Fasting blood samples (5 mL) were collected from the subjects via direct venous puncture, put into tubes containing sodium citrate, and then centrifuged at 2,000 × g for 10 min. The supernatant (plasma) was then transferred carefully into tubes, which were stored in the refrigerator at -80°C. mRNAs were extracted from the plasma samples using the miRNeasy Plasma Kit (Qiagen). Both poly-(A) tailing and reverse transcription were performed on the samples with the miScript Reverse Transcription Kit (TIANGEN). miR-126 was quantified by quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay, and U6 RNA was used as the miRNA internal control. Each reaction was performed using a miRNA-specific forward primer and a universal reverse primer according to the protocol of the manufacturer (TIANGEN). The primers were miR-126 forward: 5'-CGGGCCATTATTACTTTTG -3'; U6 forward: 5'-CTCGCTTTCGGCAGCACA-3'. Each reaction was performed in a total volume of 20 uL: 10.0 µL TaqMan® Fast Advanced Master Mix (2×), 0.5 µL miRNA-F (10 µM), 0.5 µL Universal miRNA-R (10 µM), 0.5 µL Universal Taqman probe (10 µM), 1.0 µL template DNA and nuclease-free H2O to adjust the volume. The PCR reaction was performed as follows: 50°C for 2.0 min; 95°C for 20 sec, followed by 40 cycles (95°C for 5 sec; 60°C for 25 sec). Relative gene expression levels were analysed using the formula 2^(-ΔΔCt), where ΔCT = CT (target gene) − CT (control), and this was repeated three times for each sample.

Western blot method for Spred-1 and PIK3R2

The whole blood total protein extraction kit (BB-3410, BestBio) was used to extract the total protein of the fasting blood sample. The bicinchoninic acid (BCA) quantitative kit was used to quantify the total protein. Protein concentrations were determined using a BCA protein assay kit (P0010, Thermo Fisher Scientific).
**ELISA assay for plasma VEGF levels**

All fasting blood samples (5 mL per patient) were collected via a direct venous puncture, placed into tubes containing sodium citrate, and then centrifuged at 2,000 × g for 10 min. The layer of the supernatant (plasma) was carefully transferred into other tubes and stored at −20°C. We used the Human VEGF ELISA Kit (R&D Systems) to measure the plasma levels of VEGF, following the manufacturer’s instructions. Absorbance was measured at 450 nm (primary wavelength).

**Other variables of interest**

Several clinical characteristics were compared between the groups:

1. **demographics (age and sex) and medical histories, including hypertension (according to self-report, available medical records, taking antihypotensive medication, systolic blood pressure ≥ 140 mmHg on a different day, or diastolic blood pressure ≥ 90 mmHg on a different day), diabetes (according to self-report, available medical records, taking antidiabetic medication, or fasting blood glucose ≥ 7.0 mmol/L), coronary heart disease (diagnosed by self-report or available medical records), and hyperlipidemia (diagnosed according to in-hospital tests or medical records, meeting at least one of the following criteria: blood cholesterol ≥ 6.2 mmol/L; LDL-C ≥ 4.1 mmol/L; blood triglyceride ≥ 2.3 mmol/L; or HDL-C < 1.0 mmol/L);**

2. **BMI (kg/m²); smoking, defined as regularly smoking (smoking ≥ 1 cigarette/day on average for longer than six months) or occasionally smoking (smoking more than four times a week but less than one cigarette/day on average);**

3. **fasting blood sample tests, including cholesterol, triglyceride, LDL-C, HDL-C, glucose, creatinine, and homocysteine;**

4. **medication histories, including aspirin, clopidogrel, ACEI/ARBs, statins, CCB, and beta-blockers.**

**Statistical analyses**

The continuous variables are expressed as mean ± standard deviation, and the categorical variables are expressed as frequencies. The Kolmogorov–Smirnov test was used to test whether the data were normally distributed. The differences in continuous clinical characteristics between the groups were assessed using the Student t-test or Mann–Whitney U test. Associations between categorical variables were tested by Pearson’s χ² test. Associations of miR-126, Spred-1, PIK3R2, VEGF-A with collateral grade were assessed using the Spearman correlation test. Associations of miR-126 with VEGF, Spred-1 and PIK3R2 were also analysed with Spearman correlation test because: (1) data on miR-126, Spred-1, and PIK3R2 do not have a normal distribution; (2) to keep consistency with the previous analysis (association of miR-126 and other markers with CCC status).

Receiver operating characteristic (ROC) curves were established to evaluate the predictive power of circulating miR-126 for the CCC status of patients. The area under the curve (AUC) was used to assess the predictive power. We only performed univariate analysis for three reasons: firstly, patients with severe organ dysfunction, liver diseases, tumours and other diseases which might affect circulating biomarkers of interest were excluded from the study; secondly, the baseline characteristics, including demographic factors, medical histories and laboratory tests which might have an influence on miR-126 level were generally comparable between the good CC group and the poor CCC group; and thirdly, the small study sample further restrained our statistical power to perform multivariate analysis. Statistical analyses were conducted using IBM SPSS Statistics 19, and p < 0.05 was considered statistically significant.

**Results**

**Baseline characteristics**

Of 80 patients examined for eligibility, 10 were excluded (eight with acute cerebral infarction, one with tumour, and one with severe systemic organ disease). Of the 70 patients confirmed eligible, two were excluded due to refusing consent. So, in total 68 patients were included in this study, 44 with good CCC and 24 with poor CCC. All enrolled patients were found > 70% stenosis or occlusion, via TCD, CTA, or MRA,
Table 1. Clinical characteristics and biochemical parameters of patients

<table>
<thead>
<tr>
<th>Variables</th>
<th>ASITN/SIR grade</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Good CCC (n = 44)</td>
<td>Poor CCC (n = 24)</td>
</tr>
<tr>
<td><strong>Clinical characteristics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (y)</td>
<td>59.52 ± 9.45</td>
<td>62.29 ± 8.75</td>
</tr>
<tr>
<td>Male n (%)</td>
<td>35 (79.5%)</td>
<td>18 (75%)</td>
</tr>
<tr>
<td>BMI (kg/m2)</td>
<td>25.39 ± 3.21</td>
<td>25.54 ± 3.24</td>
</tr>
<tr>
<td>Hypertension n (%)</td>
<td>30 (68.2%)</td>
<td>20 (83.3%)</td>
</tr>
<tr>
<td>Diabetes n (%)</td>
<td>11 (25%)</td>
<td>10 (41.7%)</td>
</tr>
<tr>
<td>Coronary heart disease n (%)</td>
<td>10 (22.7%)</td>
<td>4 (16.7%)</td>
</tr>
<tr>
<td>Smoking n (%)</td>
<td>26 (59.1%)</td>
<td>13 (54.2%)</td>
</tr>
<tr>
<td>Drinking n (%)</td>
<td>16 (36.4%)</td>
<td>11 (45.8%)</td>
</tr>
<tr>
<td>Hyperlipemia n (%)</td>
<td>18 (40.9%)</td>
<td>6 (25%)</td>
</tr>
<tr>
<td><strong>Laboratory index</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TC (mmol/l)</td>
<td>4.03 ± 0.93</td>
<td>4.15 ± 1.14</td>
</tr>
<tr>
<td>TG (mmol/l)</td>
<td>1.84 ± 1.11</td>
<td>1.60 ± 0.68</td>
</tr>
<tr>
<td>LDL-C (mmol/l)</td>
<td>2.34 ± 0.71</td>
<td>2.29 ± 1.02</td>
</tr>
<tr>
<td>HDL-C (mmol/l)</td>
<td>0.98 ± 0.21</td>
<td>1.10 ± 0.44</td>
</tr>
<tr>
<td>Glu (mmol/l)</td>
<td>5.98 ± 2.02</td>
<td>6.08 ± 1.77</td>
</tr>
<tr>
<td>Creatinine (μmol/l)</td>
<td>66.23 ± 13.64</td>
<td>60.08 ± 12.92</td>
</tr>
<tr>
<td>Homocysteine(umol/l)</td>
<td>14.56 ± 8.99</td>
<td>16.81 ± 10.33</td>
</tr>
<tr>
<td><strong>Medication history</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin n (%)</td>
<td>44 (100%)</td>
<td>24 (100%)</td>
</tr>
<tr>
<td>Clopidogrel n (%)</td>
<td>38 (86.4%)</td>
<td>24 (100%)</td>
</tr>
<tr>
<td>ACEI/ARBs n (%)</td>
<td>9 (20.5%)</td>
<td>4 (16.7%)</td>
</tr>
<tr>
<td>Statin n (%)</td>
<td>44 (100%)</td>
<td>24 (100%)</td>
</tr>
<tr>
<td>CCB n (%)</td>
<td>8 (18.2%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Beta-blocker n (%)</td>
<td>8 (18.2%)</td>
<td>7 (29.2%)</td>
</tr>
</tbody>
</table>

in at least one major intracranial artery, and were advised to perform digital subtraction angiography (DSA) to verify if interventional therapy was justified. The distribution of cerebral vascular stenosis/occlusion among all patients in both groups are shown in the supplement. Their clinical characteristics, biochemical parameters and medication history, including age, BMI, sex, rates of hypertension, coronary heart disease, diabetes mellitus and hyperlipemia, smoking history, drinking history, fasting glucose, and lipid profiles including LDL, HDL, TG, TC, homocysteine and creatinine, are set out in Table 1. The number of patients who were taking aspirin, clopidogrel, ACEIs/ARBs, statins and beta-blockers did not differ between the two groups. The difference in the calcium antagonist of medication history between the two groups was statistically significant (p < 0.05).

Levels of plasma miR-126, VEGF, Spred-1 and PIK3R2 in patients classified by CCC status

The concentrations of plasma VEGF-A in the good CCC group and the poor CCC group were 103.66 ± 8.00 pg/ml and 75.82 ± 15.69 pg/ml, respectively. Compared to the poor CCC group, the plasma level of VEGF was significantly higher in the good CCC group (p < 0.05) (Fig. 1A).

Subsequently, we tested the levels of plasma miR-126, Spred-1 and PIK3R2 in patients with intracranial artery occlusion or stenosis of ≥ 70% according to their CCC status. Results showed that the level of plasma miR-126 was 1.81-fold higher in the good CCC group (14.76 ± 11.91 pg/ml) than in the poor CCC group (8.17 ± 4.45 pg/ml, p < 0.05) (Fig. 1B). Moreover, the protein level of Spred-1 and PIK3R2 in plasma was lower in the good CCC group than in the poor CCC group (Spred-1:0.23 ± 0.09 pg/ml for good CCC group, 0.83 ± 0.12 pg/ml for poor CCC group; PIK3R2: 0.22 ± 0.15 pg/ml for good CCC group, 0.65 ± 0.23 pg/ml for poor CCC group) (Fig. 2).
Figure 1. Comparison of plasma miR-126 and VEGF levels between good and poor CCC groups. A. Plasma level of VEGF in patients; B. Plasma level of miR-126 in patients

Figure 2. Protein level of Spred-1 and PIK3R2

Figure 3. Correlation between miR-126 and VEGF and ASITN/SIR score

We further investigated the correlation of miR-126 and VEGF with ASITN/SIR score, which was used to evaluate the degree of CCC. As shown in Figure 3, there was a positive correlation between miR126 and VEGF and ASITN/SIR score (R = 0.595, p < 0.01). Conversely, ASITN/SIR score was negatively correlated with Spred-1 (R = -0.817, p < 0.01) and PIK3R2 (R = -0.513, p = 0.01) (Fig. 4).

Correlation between miR-126 and VEGF, Spred-1 and PIK3R2

To explore the mechanism of miR-126 in improving collateral circulation, we analysed the correlation between miR-126 and VEGF, Spred-1 and PIK3R2. There was a positive correlation between miR-126 and VEGF, Spred-1 and PIK3R2. However, the correlation between plasma miR-126 and Spred-1 and PIK3R2 was not significant (Fig. 6, 7).
**Comparison of predictive power of miR-126 for CCC status**

To compare the predictive power of plasma miR-126 for CCC status, we performed ROC analysis for the patients. As shown in Figure 8, the AUC for miR-126 was 0.328 (95% CI: 0.158–0.498; p = 0.067).

**Discussion**

In this study, we found that plasma miR-126 and VEGF were significantly higher in patients in the good CCC group than in those in the poor CCC group. In contrast, plasma Spred-1 and PIK3R2 levels were lower in patients in the good CCC group. In addition, miR-126 and VEGF were positively correlated with ASITN/SIR, whereas Spred-1 and PIK3R2 were negatively correlated with ASITN/SIR. However, miR-126 might not be an independent predictor for CCC, as the AUC of the marker for CCC status was only 0.328 (95% CI: 0.158–0.498; p = 0.067).
miR-126, the angiogenesis-related miRNA, is regarded as one of the main regulators of physiological angiogenesis. [13, 17, 18]. Several recent studies have identified that miR-126 promotes VEGF expression by suppressing Spred-1 and PIK3R2 expression [14], which contributes to angiogenesis [19–22]. Nie et al. [23] reported that plasma miR-126 level is positively correlated with CCC formation and is an independent predictor of its development in patients with severely narrowed coronary arteries. To date, it has not been reported whether miR-126 can be used as a biomarker for cerebrovascular collateral circulation. We first found that plasma miR-126 and VEGF were significantly higher in patients in the good CCC group compared to the poor CCC group. This finding indicates that higher levels of miR-126 and VEGF in the blood may be associated with better cerebrovascular collateral circulation. Our ROC analysis found an AUC value of 0.328 with a p-value of 0.067, indicating that miR-126 might not be an independent predictor for CCC, given its low predictive value.

Conclusions

Plasma miR-126 level may be related to better CCC formation accompanied by upregulation of VEGF and reduced Spred-1 and PIK3R2 protein expression. However, miR-126 might not be an independent predictor for CCC, given its low predictive value.

Funding: This work was funded by the project of the Natural Science Foundation of Inner Mongolia Autonomous Region (No. 2017MS0805).

References:


